Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: Relationships to host factors, cellular restoration, and virologic end points

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 799-807

  Wu, Hulin ^b   Kuritzkes, Daniel R ^c   McClernon, Daniel R ^c   Kessler, Harold ^c   Connick, Elizabeth ^c   Landay, Alan ^c   Spear, Greg ^c   Heath Chiozzi, Margo ^c   Rousseau, Franck ^a   Fox, Lawrence ^c   Spritzler, John ^c   Leonard, John M ^c   Lederman, Michael M ^c  

^a Triangle Pharmaceuticals   (United States)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MATHEMATICAL MODEL; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADP-RIBOSYL CYCLASE; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV-1; HUMANS; IMMUNOGLOBULIN G; MEMBRANE GLYCOPROTEINS; NAD+ NUCLEOSIDASE; RNA, VIRAL;

EID: 0011419832     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314670     Document Type: Article

References (26)

1. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
2. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
3. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-91.
4. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type I infection. Nature 1995;373:117-22.
5. Cavert W, Notermans WD, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4.
6. Wu H, Kuritzkes DR, St Clair M, et al. Interpatient variation of viral dynamics in HIV-1 infection: modeling results of AIDS Clinical Trials Group Protocol 315 [abstract]. In: Program and abstracts: First International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication (St. Petersburg, FL). San Diego: International Medical Press 1997:6-67.
7. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-9.
8. Van Gemen B, van Beuningen R, Nabbe A, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods 1994;49:157-68.
9. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-9.
10. Davidian M, Giltinan DM. Nonlinear models for repeated measurement data. New York: Chapman & Hall, 1995.
11. Wu H, Ding AA, DeGruttola V. Estimation of HIV dynamic parameters. Stat Med 1998;17:2463-85.
12. Wu H, Ding AA. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 1999 (in press).
13. Stram DO, Lee JW. Variance components testing in the longitudinal mixed effects model. Biometrics 1994;50:1171-7.
14. Spear GT, Takefman D, Sharpe S, et al. Antibodies to the V3 loop of the HIV-1 envelope proteins contribute a major proportion of the immune effector functions mediated by serum antibodies. Virology 1994;204:609-15.
15. Hoetelmans MW, Reijers MHE, Weberling GF, et al. The rate of decline of HIV-1 RNA in plasma correlates with nellinavir concentrations in plasma [abstract 42259]. In: Program and abstracts: XII International Conference on AIDS, Geneva, 1998.
16. Connick E, Lederman MM, Kotzin B, et al. Immunologic effects of 48 weeks of AZT/3TC/ritonavir[abstract LB14]. In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Infectious Diseases Society of America, 1998.
17. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998;102:79-87.
18. Anderson J, Fehniger T, Patterson BK, et al. Downregulation of cytokine production in lymphoid tissue following successful HIV suppressive therapy [abstract 159]. In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Infectious Diseases Society of America, 1998.
19. Bucy RP, Kilby JM, Derdeyn CA, et al. Analysis of lymph node biopsies in HIV-infected patients before and after HAART [abstract 519]. In: 5th Conference on Human Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Washington, DC: Infectious Diseases Society of America, 1998.
20. Keita-Perse O, Roger PM, Pradier C, Pugliese P, Cottalorda J, Dellamonica P. Does viral load at initiation of tritherapy influence the increase of CD4 T cell count? A preliminary report [abstract]. In: Program and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
21. Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS 1998;12:1483-90.
22. Neumann A. Helper/target threshold model for AIDS progression predictions for dilatory vaccine and therapy interruption vaccination [abstract]. In: Program and abstracts of the 5th annual HIV Dynamics and Evolution Conference, Santa Fe, NM, 1998.
23. + T cells, Immunol Today 1996;17:217-24.
24. + T cells. Science 1995;270:1811-5.
25. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987; 328:345-8.
26. + levels: results of 6 years of follow up. J Acquir Immune Defic Syndr 1993;6:904-12.